To investigate the impact of DHODH upregulation on the susceptibility to UVB-induced skin cancer, DHODH activity was inhibited using LFN, a non-specific inhibitor of DHODH and an FDA-approved drug for the treatment of rheumatoid arthritis. This evidence concerns the gene DHODH and rheumatoid arthritis.